A Major Win for Local Healthcare: Sri Lanka Prepares to Manufacture Its Own InsulinIn a major boost for Sri Lanka’s healthcare system and economy, Premium International Injectable (Pvt) Ltd has officially completed the construction of a landmark, state-of-the-art pharmaceutical manufacturing plant at the Koggala Export Processing Zone in Galle.Representing an investment of over Rs. 3 billion, this facility marks a vital turning point in reducing the island nation’s dependency on imported life-saving medicines.A Powerful Step Toward Self-SufficiencyCurrently, Sri Lanka is forced to import 85% to 90% of all medicines required by its public hospital network, relying on local producers for just 10% to 15%. Global supply chain shocks—experienced during the COVID-19 pandemic and the economic crisis—exposed severe vulnerabilities in supplying critical drugs to hospitals.The government has declared expanding domestic pharmaceutical production and boosting healthcare exports a top priority for the coming decade. The new plant directly targets these vulnerabilities: * Domestic Production of Insulin: The facility will locally manufacture high-grade insulin, critical for managing diabetes across Sri Lanka. * Expanding Essential Medicine: Beyond insulin, production lines will cover anesthetics, painkillers, and eventually grow to manufacture up to 33 essential pharmaceutical products. * Timeline for Operations: With construction complete, the facility is undergoing strict international regulatory and validation processes, with full production slated to begin in 2027.Company Executives Mark the MilestoneTo inspect the completed facility and launch the setup phase, senior leaders from Premium International Injectable hosted an official site visit.The executive team in attendance included: * Thushira Radella — Managing Director * Aseem Kamtham — General Manager * Raveen Peiris — Finance Manager * Nuwan Gamage — Human Resources Manager * G.D.P. Gunaratne — Public Relations Officer …along with other top company officials and industry delegates.Economic Benefits for Sri LankaThis project represents far more than just drug manufacturing; it provides strong long-term economic gains: * Retaining Foreign Currency: By producing high-demand injectable medications at home, millions of dollars in foreign exchange will be saved every year. * High-Skilled Job Growth: The plant will generate scores of technical, specialized jobs for local pharmacists, chemical engineers, lab technicians, and operational staff in the Galle region. * Export Potential: After meeting domestic hospital demands, Sri Lanka will be positioned to export specialized injectable pharmaceuticals across the South Asian region, introducing a strong new source of export revenue.